1 Improved NAAT assay for the diagnosis of onchocerciasis and its use for

2 detection of circulating cell free DNA

3 Sasisekhar Bennuru¹, Frimpong Kodua^{1**}, Eric Dahlstrom², Thomas B Nutman¹

4

5 **Affiliations:**

⁶ ¹Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD USA

⁷²Genomics Unit, Research Technologies Branch, NIAID, NIH, Hamilton, USA.

8 **Howard University Hospital, Department of Internal Medicine, Washington DC, USA

9

10 Abstract

- 11 Mass drug administration (MDA) programs aimed at control and elimination of
- 12 onchocerciasis relies on annual or semi-annual distribution of Ivermectin (IVM) that
- 13 target the microfialarial (mf) stage of the parasite Onchocerca volvulus. The co-
- 14 endemicity of onchocerciasis with other filarial species often leads to interruptions in the

15 control programs. A much-needed tool for the elimination efforts are sensitive diagnostic

- 16 assays that can help differentiate from other co-endemic filarial infections or
- 17 xenomonitoring approaches. qPCR assays targeting highly repeated elements in the
- 18 genomes have allowed for increased sensitivity of detection that are pathogen-specific.
- 19 Utilizing NGS data, qPCR assays were designed to target 15 highly repeated targets
- 20 from O. volvulus and 11 from O. ochengi. The two most sensitive and specific repeats
- 21 Ov15R and Ov16R from O. volvulus and OoR1 and OoR5 from O. ochengi, were
- 22 selected for further testing.

23	The analytical sensitivity of both Ov15R and Ov16R were similar with limits of detection
24	(LOD) at 1 fg of O. volvulus genomic DNA (gDNA), and 100% specificity and ~32-fold
25	sensitive than O-150 qPCR. Similarly, OoR1 and OoR5 had LOD of 100 fg of O.
26	ochengi gDNA. Using DNA obtained previously from skin snips, Ov16R identified 17
27	additional samples as positive for infections when compared to O-150.
28	Further, to eliminate the need for time-dependent sample acquisition, we evaluated the
29	efficiency of plasma-derived circulating cell-free DNA (ccfDNA) to detect O. volvulus
30	infections and as a potential modality for testing cure of infection. Plasma-derived
31	ccfDNA failed to amplify Ov16R. In contrast using a small set of urine-derived ccfDNA
32	samples from Ov-infected individuals had varying levels of detectability as early as 12-
33	24 hours post-treatment. To enable processing of larger volumes of urine for better
34	sensitivity, a modified chitosan-based filter technique was developed as proof-of-
35	concept that efficiently captured gDNA from 1-15ml of urine.
36	Interestingly, Ov15R, Ov16R and O-150 map to the same contigs of O. volvulus
37	genome. This prompted the redesign of O-150 qPCR that resulted in O-150-New qPCR
38	assay that performs on par with Ov15R/Ov16R, thus offering more sensitive and
39	specific diagnosis of O. volvulus that can easily be configured to field-friendly formats
40	such as LAMP or RPA.

41

42 Introduction

Onchocerca volvulus is a filarial parasite that causes onchocerciasis or more often
known as 'river blindness' and is transmitted by the bites of *Simulium* blackfly species
primarily endemic to sub-Saharan Africa. Control efforts for elimination of the disease as

a major public health concern relies on the mass drug administration (MDA) programs with annual or semi-annual distribution of Ivermectin (IVM). Only the microfilarial (mf) stages of the parasite are effectively targeted using IVM that help to reduce disease burden and block transmission to the blackfly vectors (*Simulium* sp). Based on the microfilarial prevalence, endemic regions can be broadly categorized into hypoendemic (<30-35%), mesoendemic (30-35% to 60%) and hyperendemic (\geq 60%).

A much-needed tool for the elimination efforts is a specific and sensitive 52 53 diagnostic assay that can verify if the levels of transmission of the disease are low 54 enough to warrant the cessation of MDA or in regions of post-MDA surveillance for 55 monitoring resurgence of infection. The use-case scenario for the assay relies on the 56 assay(s) to have high sensitivity and specificity, to detect very low-levels of mf densities 57 while being able to discriminate between closely related co-endemic major filarial 58 parasites that infect humans such as Loa loa, Wuchereria bancrofti, Mansonella 59 perstans and the bovine filarial parasite Onchocerca ochengi that is also transmitted by 60 the same vector species. Another major concern is the presence of Loa loa microfilariae in the skin-snips of infected individuals in co-endemic areas [1] that often lead to false 61 62 interpretations.

Historically, the identification of microfilariae in the skin snips by microscopy was
the 'gold standard' for diagnosis of infection. Though skin snip microscopy is 100%
specificity it is plagued with low sensitivity (estimated at 20%) esp. in areas with low mf
densities[2].

The guidelines from World Health organization (WHO) for stopping MDA and verifying
elimination of onchocerciasis as a major public health concern recommends serological

69 evaluation for Ov16 by ELISA or rapid diagnostic test (RDT) [3], where the seropositivity 70 to Ov16 in children younger than 10 years should be <0.1% and positivity of pool screen 71 PCR of at least 6000 black fly heads to be <0.05%, the diagnostic performance 72 thresholds of which depend on multiple factors [3, 4]. The Ov-16 antibody test 73 determines the presence of IgG4 antibodies to Ov-16 as a marker of exposure to the 74 parasite [5-8]. Entomological screening for the presence of infective L3 larvae in the 75 vector population relies on the PCR based amplification of O-150 repeat family region of 76 parasite DNA [9-11]. Though there is some conservation of the O-150 tandem repeats 77 sequences across the Onchocerca spp., the tandem repeats not only vary in the 78 number but also not always identical repeats. In addition to the detection of O-150, 79 assays based on real-time qPCR and loop mediated isothermal amplification (LAMP) 80 have been developed to detect O. volvulus DNA in the skin [12]. Skin snip evaluation 81 by PCR could be used to also differentiate active infection from exposure to the parasite 82 where the prevalence of Ov-16 seropositivity is > 0.1% [3]. However, skin snips being 83 more invasive in nature are becoming increasingly unpopular and often refused by 84 endemic communities [13]. Recent studies explored the detectability of circulating filarial DNA for B. malayi [14], L. loa [15] or Onchocerca spp [16]. Though parasite-derived 85 86 miRNAs were detected in the plasma of O. volvulus infected individuals, their detection 87 as a biomarker has been challenging and were determined to be insufficient tools or as 88 biomarkers of treatment efficacy for O. volvulus [16, 17]. Detecting circulating cell-free 89 DNA in body fluids (serum/plasma or urine) provides a promising alternative where sample collection is more convenient or less invasive. 90

91 In this study, we explored the utility of repeatexplorer pipeline that has previously 92 been shown to identify targets that are not only more sensitive in detecting infections 93 [15, 18-21] and specific, but also enable the monitoring of treatment efficacy [15]. 94 95 96 **Methods** 97 Samples 98 All archived serum/plasma or urine samples were obtained as part of National Institute 99 of Allergy and Infectious Diseases' Institutional Review Board-approved protocols for 100 filaria-infected patients (NCT00001230) and healthy donors (NCT00090662), that were 101 from previous studies [22, 23] and stored at -80C. As part of routine clinical care, 102 informed written consent was obtained from all subjects. Archived DNA samples from 103 skin snips were from previous studies [1], that received ethical clearance from the 104 Cameroon National Ethics Committee for Research in Human Health (No. 105 2013/11/370/L/CNERSH/SP), and an administrative authorization was granted by the 106 Ministry of Public Health (D30- 571/L/MINSANTE/SG/DROS/CRSPE/BBM). All eligible volunteers signed an informed consent form for their participation in the study, including 107 108 for the further use of their samples. 109 110 Target identification and Assay Design 111 Sequence read archives (SRA) from BioProjects PRJEB513, PRJEB17785 and PRJNA289926 for O. volvulus and BioProject PRJEB23566 for O. ochengi were 112

processed to trim, clean and obtain paired reads. The RepeatExplorer [24, 25] pipeline

114	was used to analyze the paired reads and generate highly repeated contigs (numbered
115	with a prefix of "Ov" and suffix "R"). The most promising contigs for O. volvulus (n=15)
116	and O. ochengi (n=11) with >1000x coverage, minimal length of 100 base pairs and
117	minimal homology with other helminths and human were selected (Table S1). O-150
118	qPCR was also redesigned to improve the assay. PCR assays were designed for these
119	selected sequences using the PrimerQuest Tool (Integrated DNA Technologies, IDT),
120	and custom oligos synthesized for screening with real-time qPCR assays.
121	
122	ccfDNA extraction and real-time PCR
123	Circulating cell-free DNA was extracted from 100, 250, 500 or 1000 μl of plasma using
124	the MinElute ccfDNA kit or its automated version Viral/Pathogen DSP kit for
125	Qiasymphony. The samples were eluted in a final volume of 20 μI for MinElute and 60 μI
126	on the Qiasymphony.
127	DNA extractions from 1 ml of urine were as mentioned above, while larger
128	volumes were performed using a chitosan-modified filter paper technique [26, 27] with
129	slight modifications. Briefly, Fusion 5 filter paper (Whatman) were washed in 30 ml 0.2
130	M NaOH for 5 minutes, washed with 50 ml deionized water (3x) and dried under
131	vacuum at 45° C. The filters were soaked in chitosan (0.25%) dissolved in 0.1 M acetic
132	acid for 16 hours at room temperature on a rotary shaker. The membranes were
133	washed (3x) in deionized water and dried under vacuum at $45^{\circ}C$. 4-mm diameter discs
134	of chitosan-functionalized membranes and Whatman GB003 cellulose paper were made
135	using biopsy punch. A 2 mm-diameter opening was made in a female Luer cap (Cole
136	Parmer, Vernon Hills, IL) using a biopsy punch. The 4-mm GB003 cellulose membrane

137 disc (as backing support membrane) followed by the chitosan-functionalized disc were 138 positioned in the luer cap. Urine samples mixed 1:1 with 50 mM MES (pH 5.0) were 139 passed through the luer caps using 20 ml syringes at a flow rate of 0.5 ml per minute 140 using the PHD ULTRA (Harvard Apparatus). The DNA trapped on the chitosan-141 functionalized membrane was retrieved by boiling the disc in 50 μ l of deionized water. 142 qPCR was performed in guadruplicates using an ABI 7900 sequence detection 143 system using Tagman fast chemistry reagents (Applied Biosystems, Carlsbad, CA, USA) 144 and primer/probe sets described in **Table 1**. Amplification conditions were 20 seconds 145 at 95°C followed by 40 cycles of 1 second at 95°C and 20 seconds at 60°C. An internal 146 plasmid control [28] was spiked into all samples prior to ccfDNA extraction to exclude 147 false negatives due to qPCR inhibition. For a sample to be considered as positive at least three of the 4 replicates needed to positive. An internal plasmid control [28] was 148 149 spiked into all samples prior to ccfDNA extraction to exclude false negatives due to 150 qPCR inhibition. 151

152 Statistical analyses

All statistical analyses were performed using GraphPad Prism v8. Unpaired samples
were compared using Mann-Whitney test and paired analyses were performed with
Wilcoxon matched-pairs signed rank test.

156

157 **Results**

158 O. volvulus and O. ochengi target identification

159 The repeatexplorer pipeline [24, 25] resulted in the identification of several highly 160 repetitive contigs in the genomes of O. volvulus and O. ochengi of which, thirteen of the 161 most highly represented ones for O. volvulus and eleven of the O. ochengi contigs were 162 selected to be screened by qPCR (Figure 1). Preliminary screening with 10-fold dilutions of 1ng/ul of O. volvulus genomic DNA (Ov gDNA) indicated that Ov15R, 163 164 Ov16R, Ov21R, Ov31R, Ov36R and Ov54R had better sensitivity than the other repeat 165 contigs (Figure 1A). Moreover, these six assays had better sensitivity (lower Ct values) 166 compared to the current gold standard O-150 gPCR (Figure 1B), of which Ov15R and Ov16R were chosen for being the most sensitive assays. Ov15R and Ov16R assays 167 168 were similar in their limits of detection (1fg of gDNA) while maintaining specificity with 169 gDNA of B. malayi, L. loa, W. bancrofti, M. perstans and O. ochengi (Figure 1C). 170 The eleven O. ochengi repeat contigs were screened with 2 assays designed for 171 each contig (R1-R22), of which R1 and R5 (henceforth referred to as OoR1 and OoR5) 172 were the most sensitive (lowest Ct value) when screened with 10 pg of O. ochengi 173 gDNA (Figure 1D). Screening of OoR1 and OoR5 with gDNA standards indicated the 174 LOD of 100 fg with O. ochengi gDNA while maintaining specificity with O. volvulus qDNA (Figure 1E). 175

176

177 Relationship between O-150 and Ov15R/Ov16R

Because Ov15R and Ov16R had better sensitivity (lower Ct values) compared to O-150 qPCR assay (**Figure 2A**), combinations of Ov15R and/or Ov16R were tested with O-150 but did not yield any enhancements in the limits of detection. Sequence analyses suggested that the selected *O. volvulus* contigs might be related somehow to O-150 in

182	that they all mapped to one end of OVOC_OO_000013, OVOC_OO_00548 or
183	OVOC_OM1b of the O. volvulus genome. This prompted a re-designing of the O-150
184	assay, where all the new assays (O-150 N1-N5) performed much better than the
185	original O-150 assay and comparable to Ov15R/Ov16R (Figure 2B). The O-150 N1
186	(henceforth called O-150New) was used for all further comparative analyses when
187	needed. It is not clear as to what drives this new assay to be more sensitive but
188	compared to the original oligos, the major observable change was the number of
189	locations that O-150New reverse could bind in the O-150 repeat region (Acc. No.
190	J04659.1) (Figure S1). Since Ov15R and Ov16R were essentially similar, all further
191	analyses were done with Ov16R.
192	
193	Efficiency of Ov16R with skin snip samples
194	The efficacy of Ov16R was evaluated with archived DNA extracted from skin snip
195	samples from two previous studies: 1) individuals with nodding syndrome that were
196	previously screened with O-150 qPCR and 2) from individuals living in an area co-
197	endemic for loiasis. As shown in Figure 3A, of the 95 samples with nodding syndrome,
198	42 (44%) were positive by O-150. Ov16R with slightly better (lower) Ct values (Figure
199	3B) was able to pick up 17 additional samples as positive for a total of 59 (62%)
200	positives (Figure 1C). Likewise, DNA extracted from skin snip samples from an area
201	co-endemic for loiasis with microfilariae in the skin snips that were previously diagnosed
202	for the vast majority as microfilariae of Loa loa and not Onchocerca volvulus, were
203	tested with Ov16R. As shown in Figure 3D, despite a modest gain in Ct values
204	compared to O-150, there were no additional positives that were detectable with

Ov16R. As expected, the O150 results correlated similarly with O-150-New and Ov16R
Ct values, with O-150-New performing similarly to Ov16R in comparison to the O-150
(Figure 3E-G).

208

209 Plasma circulating cell-free DNA (ccfDNA)

To evaluate the efficacy of detecting Ov16R or O-150-New in ccfDNA derived from

211 plasma of infected individuals, pooled plasma of infected individuals or pooled plasma

of health blood bank individuals spiked with 100 pg of gDNA were used to extract

213 ccfDNA. The ccfDNA extraction was carried out using plasma volumes of 100 µl, 250 µl,

500 μl and 1000 μl, using the MinElute ccfDNA kit (Qiagen) with elution volumes of 20

215 µl for all samples. As shown in Figure 4A, ccfDNA derived from any of the pooled

samples (and volumes) from Ecuador or Guatemala failed to amplify Ov16R. As

expected, the ccfDNA from pooled blood bank individuals were negative but the spiked

samples were highly positive for Ov16R, suggesting that the lack of detectability is likely

219 due to the absence of detectable levels of parasite-derived DNA in circulation.

220

221 Urine circulating cell-free DNA (ccfDNA)

Urine as a source of detecting the presence of ccfDNA was tested using archived
samples from previous studies (ref), that was aimed at understanding the immunological

sequelae during Mazzotti reactions post treatment with ivermectin and followed up

every 3-12 hours. ccfDNA was extracted from 1 ml of urine from 22 samples pre-

treatment (18-infected and 4-controls). As shown in Figure 4B, 8/18 (44%) samples

were positive for Ov16R at time 0. Since ivermectin targets only the microfilarial stages,

and the death of microfilariae would result in parasite-derived DNA in circulation, we screened the time-course samples for 4 individuals that were still available (2 each for samples that were negative or positive at time 0). As expected, in the two samples that were negative pre-treatment, Ov16R could be detected as early as 12-24 hours posttreatment (**Figure 4C**), that eventually clears away around 3-4 days post-treatment. In contrast, the two samples that were positive for Ov16R pre-treatment had varying levels of detectability all through the time-course (**Figure 4D**).

To evaluate if there would be any difference in the sensitivity of ccfDNA in urine that has been frozen away for two decades compared to fresh urine, we obtained more recent/fresh urine samples from 5 individuals from Cameroon. Surprisingly, ccfDNA extracted from 1 ml of all five urine samples were positive for Ov16R (Figure 4E).

239

240 Chitosan filter-based capture of ccfDNA

241 Though urine is not exactly a limiting factor in terms of sample volume, the 242 processing of larger volumes with existing kits/reagents render it highly unusable. 243 Hence to evaluate the feasibility of capturing/trapping the ccfDNA, we adapted the chitosan-modified filter paper technique (ref). Because of the non-availability of patient 244 245 derived urine samples in higher volumes, pooled normal urine (1 or 15 ml) was spiked 246 with various concentrations of O. volvulus gDNA and an internal control (IAC) and 247 ccfDNA extracted onto chitosan filters (see methods). In parallel, 1 ml of urine samples 248 with the spiked gDNA was also extracted on QiaSymphony. The filters were boiled in 30 249 ul of TE buffer (pH 8.0) to elute the DNA for qPCR detection. As shown in Figure 5, the 250 efficiency of gDNA captured from 1 ml or 15 ml of urine and subsequent detectability of

251 Ov16R were identical, indicating that it is possible to filter out larger volumes of urine,

- 252 while capturing DNA.
- 253
- 254 Discussion
- 255

256 This study reports the identification of genomic repeats enriched in the genomes of *O*.

257 volvulus and O. ochengi. Among those identified for O. volvulus, Ov16R was more

sensitive than O-150 by qPCR. Based on informatic analyses, O-150 and Ov16R are

related by way of their genomic location as they both map to one end of

260 OVOC_OO_000013, OVOC_OO_00548 or OVOC_OM1b of the O. volvulus genome.

261 The superiority of Ov16R to O-150 qPCR in terms of sensitivity was probably overcome

using RepeatExplorer pipeline that utilizes NGS data to directly infer repeated elements

that have been successfully utilized for developing highly sensitive diagnostic assays

264 [18-20], instead of assembled contigs of the genome, where highly repetitive sequences

in genome assemblies are often omitted as orphan DNA during the assembly process.

266 Diagnostic testing for onchocerciasis in regions co-endemic for Loa or 267 Mansonella spp can be challenging as mf of M. streptocerca typically migrate through 268 the skin [29], whereas mf from *M. perstans* and *L. loa* circulate in the vasculature [30]. 269 Nevertheless, microscopy analyses of L. loa can be misdiagnosed as mf of onchocerca 270 in nature especially in cases where the burden is high [1]. With the availability of better 271 repeat targets for detecting L. loa [15], M. perstans [21], the combination of Ov16R or 272 O150New would be a great tool to not only help in more accurate diagnosis but to also 273 advance the global efforts for mapping and elimination of neglected tropical diseases in

areas co-endemic for filarial infections. Another bottleneck in the molecular
xenodiagnoses or xenomonitoring is the presence of other onchocerca species (*O. ochengi*, *O. guttarosa* etc) in the vectors. The use of OoR1 or OoR5 along with Ov16R
or O150New would help differentiate *O. ochengi* from *O. volvulus*). Alternatively, the use
of OvND5 (GenBank: AY462885.1 and FM206483.1) [31] that is slightly less sensitive
but highly specific for *O. volvulus* or *O. ochengi* could be implemented as a second or
confirmatory test to rule of *O. volvulus*.

281 Circulating cell-free DNA (ccfDNA) are residual fragments of DNA present in the 282 peripheral circulation and have been used as good biomarkers in pregnancy, diabetes, 283 cancer and solid-organ transplantation (reviewed in [32-34]). Since the circulating cell-284 free DNA in the body fluids (plasma and/or urine) are short-lived and likely to be 285 excreted in urine, we evaluated the ability to detect Ov16R in plasma- and urine-derived 286 ccfDNA of infected individuals to reflect the presence of active infection as the parasites 287 release DNA (homeostatic and upon injury/death after treatment). However, we were 288 unable to detect Ov16R reliably in ccfDNA derived from 250 ul of plasma. Increasing the 289 initial of plasma to 2 ml did not alter the outcome significantly, suggesting that the 290 inability to detect Ov16R in plasma-derived ccfDNA may partly be due to the niche of O. 291 volvulus (skin-dwelling) in contrast to the blood vasculature dwelling filarial parasites 292 (W. bancrofti, B. malayi and L. loa). It is interesting that the novel repeat regions that 293 were identified earlier were also located in contigs that shared the O-150 repeat [16], 294 but were no better at detecting circulating parasite-derived DNA.

295

The kinetics of detecting Ov16R in urine after treatment with DEC and their disappearance after 72 hours correlates well with the rapid death of the microfilariae and subsequent clearance from circulation with the immunohistological and microscopical observations that the mf disappear within 3-days of microfilaricidal treatment [35, 36].

301

302 Nevertheless, in contrast to L. loa infections [15], urine proved to be a better 303 source for parasite-derived ccfDNA. While the lack of parasite derived ccfDNA in 304 plasma could be attributed to the niche of *O. volvulus* (in contrast to vascular dwelling 305 filaria such as W. bancrofti or L. loa), it is not clear as to why Ov16R was more readily 306 detectable in the limited number of more recent/fresh urine samples compared to 307 archived frozen urine samples. Previous studies demonstrated that the ccfDNA is 308 comprised of highly fragmented double stranded DNA around 150bp in length, that 309 relates to about 9,000-17,000 genome equivalents of human diploid genome in 1 ml of 310 blood [37, 38]. Though there is no established method of characterizing the nature of 311 parasite-derived ccfDNA in circulation, they are comparatively less abundant when 312 compared to the host-derived ccfDNA. The rapid turnover and estimated renal 313 clearance of ~30 minutes is an important feature of ccfDNA that can be exploited for 314 active cases of infection. The ccfDNA content is also known to vary as a function of 315 collection time, duration interval and storage conditions [39]. Prospectively, analyzing 316 larger volumes of urine samples using the chitosan filter-based method needs to be 317 evaluated for the efficiency of DNA capture. Moreover, once optimized, this would also 318 facilitate easy storage of the filters compared to storing larger volumes in freezers.

319

320 Acknowledgements

- 321 This work was supported in part by the Division of Intramural Research (DIR) of the
- 322 National Institute of Allergy and Infectious Diseases, NIH.
- 323 We thank Dr. Sara Lustigman from New York Blood Center for fresh urine samples from
- 324 Cameroon.
- 325
- 326 All data produced in the present work are contained in the manuscript

327 REFERENCES

Nana-Djeunga HC, Fossuo-Thotchum F, Pion SD, Chesnais CB, Kubofcik J, Mackenzie CD,
 et al. Loa loa Microfilariae in Skin Snips: Consequences for Onchocerciasis Monitoring and
 Evaluation in L. loa-Endemic Areas. Clin Infect Dis. 2019;69(9):1628-30. doi: 10.1093/cid/ciz172.
 PubMed PMID: 30861060; PubMed Central PMCID: PMCPMC6792118.

Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of detection of
 microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg.

334 1989;41(4):467-71. doi: 10.4269/ajtmh.1989.41.467. PubMed PMID: 2802024.

335 3. Guidelines for stopping mass drug administration and verifying elimination of human 336 onchocerciasis - Criteria and procedures, (1 January 2016, 2016).

Group NTDMCO. The World Health Organization 2030 goals for onchocerciasis: Insights
 and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis

339 Group. Gates Open Res. 2019;3:1545. Epub 20190926. doi: 10.12688/gatesopenres.13067.1.

340 PubMed PMID: 31723729; PubMed Central PMCID: PMCPMC6820451.

Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB. An immunogenic
Onchocerca volvulus antigen: a specific and early marker of infection. Science.

343 1991;251(5001):1603-5. doi: 10.1126/science.2011741. PubMed PMID: 2011741.

Gbakima AA, Nutman TB, Bradley JE, McReynolds LA, Winget MD, Hong Y, et al.
 Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.
 Clin Diagn Lab Immunol. 1996;3(1):98-104. doi: 10.1128/cdli.3.1.98-104.1996. PubMed PMID:
 8770512; PubMed Central PMCID: PMCPMC170255.

Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E, et al. A rapid-format antibody card
test for diagnosis of onchocerciasis. J Infect Dis. 2000;182(6):1796-9. Epub 20001026. doi:
10.1086/317629. PubMed PMID: 11069258.

Solden A, Steel C, Yokobe L, Jackson E, Barney R, Kubofcik J, et al. Extended result
 reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new
 technology to improve epidemiological surveillance tools. PLoS One. 2013;8(7):e69231. Epub
 20130723. doi: 10.1371/journal.pone.0069231. PubMed PMID: 23935960; PubMed Central
 PMCID: PMCPMC3720650.

356 9. Katholi CR, Toe L, Merriweather A, Unnasch TR. Determining the prevalence of
357 Onchocerca volvulus infection in vector populations by polymerase chain reaction screening of
358 pools of black flies. J Infect Dis. 1995;172(5):1414-7. doi: 10.1093/infdis/172.5.1414. PubMed
359 PMID: 7594692.

Unnasch TR, Meredith SE. The use of degenerate primers in conjunction with strain and
species oligonucleotides to classify Onchocerca volvulus. Methods Mol Biol. 1996;50:293-303.
doi: 10.1385/0-89603-323-6:293. PubMed PMID: 8751366.

363 11. Zimmerman PA, Guderian RH, Aruajo E, Elson L, Phadke P, Kubofcik J, et al. Polymerase
364 chain reaction-based diagnosis of Onchocerca volvulus infection: improved detection of
365 patients with onchocerciasis. J Infect Dis. 1994;169(3):686-9. doi: 10.1093/infdis/169.3.686.
366 PubMed PMID: 8158053.

367 12. Alhassan A, Makepeace BL, LaCourse EJ, Osei-Atweneboana MY, Carlow CK. A simple
 368 isothermal DNA amplification method to screen black flies for Onchocerca volvulus infection.

369 PLoS One. 2014;9(10):e108927. Epub 20141009. doi: 10.1371/journal.pone.0108927. PubMed
370 PMID: 25299656; PubMed Central PMCID: PMCPMC4191976.

13. Wilson NO, Badara Ly A, Cama VA, Cantey PT, Cohn D, Diawara L, et al. Evaluation of

372 Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis

373 with Ivermectin. PLoS Negl Trop Dis. 2016;10(12):e0005198. Epub 20161207. doi:

374 10.1371/journal.pntd.0005198. PubMed PMID: 27926918; PubMed Central PMCID:

375 PMCPMC5142766.

376 14. Khowawisetsut L, Sarasombath PT, Thammapalo S, Loymek S, Korbarsa T, Nochote H, et

al. Therapeutic trial of doxycyclin plus ivermectin for the treatment of Brugia malayi naturally

infected cats. Vet Parasitol. 2017;245:42-7. Epub 20170818. doi: 10.1016/j.vetpar.2017.08.009.
PubMed PMID: 28969836.

380 15. Bennuru S, Kodua F, Drame PM, Dahlstrom E, Nutman TB. A novel, bioinformatically

informed highly sensitive NAAT assay for the diagnosis of loiasis and its use for detection of

circulating cell free DNA. J Infect Dis. 2023. Epub 20230527. doi: 10.1093/infdis/jiad186.
 BubMed PMID: 37243712

383 PubMed PMID: 37243712.

384 16. Macfarlane CL, Quek S, Pionnier N, Turner JD, Wanji S, Wagstaff SC, et al. The

insufficiency of circulating miRNA and DNA as diagnostic tools or as biomarkers of treatment

efficacy for Onchocerca volvulus. Sci Rep. 2020;10(1):6672. Epub 20200421. doi:

387 10.1038/s41598-020-63249-4. PubMed PMID: 32317658; PubMed Central PMCID:
 388 PMCPMC7174290.

389 17. Tritten L, Burkman E, Moorhead A, Satti M, Geary J, Mackenzie C, et al. Detection of 390 circulating parasite-derived microRNAs in filarial infections. PLoS Negl Trop Dis.

391 2014;8(7):e2971. Epub 20140717. doi: 10.1371/journal.pntd.0002971. PubMed PMID:

392 25033073; PubMed Central PMCID: PMCPMC4102413.

393 18. O'Connell EM, Harrison S, Dahlstrom E, Nash T, Nutman TB. A Novel, Highly Sensitive 394 Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and

395 Ventricular Neurocysticercosis and for Assessing Responses to Treatment. Clin Infect Dis.

396 2020;70(9):1875-81. doi: 10.1093/cid/ciz541. PubMed PMID: 31232448; PubMed Central
 397 PMCID: PMCPMC7156770.

39819.Pilotte N, Maasch J, Easton AV, Dahlstrom E, Nutman TB, Williams SA. Targeting a highly

399 repeated germline DNA sequence for improved real-time PCR-based detection of Ascaris

400 infection in human stool. PLoS Negl Trop Dis. 2019;13(7):e0007593. Epub 20190722. doi:

401 10.1371/journal.pntd.0007593. PubMed PMID: 31329586; PubMed Central PMCID:

402 PMCPMC6675119.

403 20. Sears WJ, Qvarnstrom Y, Dahlstrom E, Snook K, Kaluna L, Balaz V, et al. AcanR3990 404 gPCR: A Novel, Highly Sensitive, Bioinformatically-Informed Assay to Detect Angiostrongylus

405 cantonensis Infections. Clin Infect Dis. 2021;73(7):e1594-e600. doi: 10.1093/cid/ciaa1791.
406 PubMed PMUD: 2225.2651: PubMed Control PMC/D: PMCPMC8402108

406 PubMed PMID: 33252651; PubMed Central PMCID: PMCPMC8492198.

Pilotte N, Thomas T, Zulch MF, Sirois AR, Minetti C, Reimer LJ, et al. Targeting a highly
repetitive genomic sequence for sensitive and specific molecular detection of the filarial

409 parasite Mansonella perstans from human blood and mosquitoes. PLoS Negl Trop Dis.

410 2022;16(12):e0010615. Epub 20221229. doi: 10.1371/journal.pntd.0010615. PubMed PMID:

411 36580452; PubMed Central PMCID: PMCPMC9833530.

412 Steel C, Lujan-Trangay A, Gonzalez-Peralta C, Zea-Flores G, Nutman TB. Immunologic 22. 413 responses to repeated ivermectin treatment in patients with onchocerciasis. J Infect Dis. 414 1991;164(3):581-7. doi: 10.1093/infdis/164.3.581. PubMed PMID: 1822959. 415 23. Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of 416 onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am 417 J Trop Med Hyg. 1985;34(3):529-36. doi: 10.4269/ajtmh.1985.34.529. PubMed PMID: 4003668. 418 Novak P, Neumann P, Pech J, Steinhaisl J, Macas J. RepeatExplorer: a Galaxy-based web 24. server for genome-wide characterization of eukaryotic repetitive elements from next-419 420 generation sequence reads. Bioinformatics. 2013;29(6):792-3. Epub 20130201. doi: 421 10.1093/bioinformatics/btt054. PubMed PMID: 23376349. 422 Novak P, Neumann P, Macas J. Graph-based clustering and characterization of repetitive 25. sequences in next-generation sequencing data. BMC Bioinformatics. 2010;11:378. Epub 423 424 20100715. doi: 10.1186/1471-2105-11-378. PubMed PMID: 20633259; PubMed Central PMCID: 425 PMCPMC2912890. 426 26. Gan W, Gu Y, Han J, Li CX, Sun J, Liu P. Chitosan-Modified Filter Paper for Nucleic Acid 427 Extraction and "in Situ PCR" on a Thermoplastic Microchip. Anal Chem. 2017;89(6):3568-75. 428 Epub 20170308. doi: 10.1021/acs.analchem.6b04882. PubMed PMID: 28230980. Rosenbohm JM, Robson JM, Singh R, Lee R, Zhang JY, Klapperich CM, et al. Rapid 429 27. 430 electrostatic DNA enrichment for sensitive detection of Trichomonas vaginalis in clinical urinary 431 samples. Anal Methods. 2020;12(8):1085-93. Epub 20200205. doi: 10.1039/c9ay02478f. PubMed PMID: 35154421; PubMed Central PMCID: PMCPMC8837197. 432 433 Deer DM, Lampel KA, Gonzalez-Escalona N. A versatile internal control for use as DNA in 28. 434 real-time PCR and as RNA in real-time reverse transcription PCR assays. Lett Appl Microbiol. 435 2010;50(4):366-72. Epub 20100122. doi: 10.1111/j.1472-765X.2010.02804.x. PubMed PMID: 20149084. 436 437 Fischer P, Buttner DW, Bamuhiiga J, Williams SA. Detection of the filarial parasite 29. 438 Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based assay. 439 Am J Trop Med Hyg. 1998;58(6):816-20. doi: 10.4269/ajtmh.1998.58.816. PubMed PMID: 440 9660471. 441 30. Zoure HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The Geographic 442 Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessment 443 Procedure for Loiasis (RAPLOA). Plos Neglect Trop D. 2011;5(6). doi: ARTN e1210 444 10.1371/journal.pntd.0001210. PubMed PMID: WOS:000292139600045. 445 Hendy A, Kruger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et al. The blackfly vectors 31. and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania. Acta Trop. 446 447 2018;181:50-9. Epub 20180202. doi: 10.1016/j.actatropica.2018.01.009. PubMed PMID: 448 29410302. Arko-Boham B, Aryee NA, Blay RM, Owusu EDA, Tagoe EA, Doris Shackie ES, et al. 449 32. 450 Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate 451 cancers. Cancer Genet. 2019;235-236:65-71. Epub 20190423. doi: 452 10.1016/j.cancergen.2019.04.062. PubMed PMID: 31105051. 453 Edwards RL, Menteer J, Lestz RM, Baxter-Lowe LA. Cell-free DNA as a solid-organ 33. 454 transplant biomarker: technologies and approaches. Biomark Med. 2022;16(5):401-15. Epub 455 20220223. doi: 10.2217/bmm-2021-0968. PubMed PMID: 35195028.

456 Padilla-Martinez F, Wojciechowska G, Szczerbinski L, Kretowski A. Circulating Nucleic 34. 457 Acid-Based Biomarkers of Type 2 Diabetes. Int J Mol Sci. 2021;23(1). Epub 20211228. doi: 458 10.3390/ijms23010295. PubMed PMID: 35008723; PubMed Central PMCID: PMCPMC8745431. 459 Buttner G, Zea-Flores G, Poltera AA, Buttner DW. Fine structure of microfilariae in the 35. 460 skin of onchocerciasis patients after exposure to amocarzine. Trop Med Parasitol. 461 1991;42(3):314-8. PubMed PMID: 1801159. 462 Darge K, Lucius R, Monson MH, Behrendsen J, Buttner DW. Immunohistological and 36. electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis 463 464 patients after ivermectin treatment. Trop Med Parasitol. 1991;42(4):361-7. PubMed PMID: 465 1796234. 37. Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): Clinical Significance and 466 Utility in Cancer Shaped By Emerging Technologies. Mol Cancer Res. 2016;14(10):898-908. Epub 467 468 20160715. doi: 10.1158/1541-7786.MCR-16-0044. PubMed PMID: 27422709. 469 38. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, et al. Androgen Receptor 470 Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in 471 Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015;21(10):2315-24. Epub 20150223. 472 doi: 10.1158/1078-0432.CCR-14-2666. PubMed PMID: 25712683. Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of 473 39. 474 obtaining a high yield of cell-free DNA from urine. PLoS One. 2020;15(4):e0231058. Epub 20200406. doi: 10.1371/journal.pone.0231058. PubMed PMID: 32251424; PubMed Central 475 476 PMCID: PMCPMC7135229.

- 477
- 478

479



482 Figure 1

481

483 Identification of Onchocerca volvulus and Onchocerca ochengi repeat elements. (A) 484 The graph depicts the screening of the identified repeat elements for limits of detection (plotted as Ct-values on the y-axis) by gPCR using dilutions of O. volvulus gDNA. (B) 485 486 The graph represents the efficiency of the top five assays targeting repeated elements 487 in comparison with O-150. (C) The graph depicts the specificity of Ov16R and Ov15R with serial dilutions of gDNA across major filarial parasites of humans. (D) The bar 488 489 graph depicts the screening of the identified repeat elements for limits of detection 490 (plotted as Ct-values on the y-axis) by qPCR using O. ochengi (blue) and O. volvulus (red) gDNA. (E) The bar graph shows the limits of detection (plotted as Ct-values on the 491 492 y-axis) of O. ochengi repeat assays (OoR1 and OoR5) by gPCR using dilutions of O. 493 ochengi (red and blue) and O. volvulus (green and black) gDNA. No amplifications were 494 set to 40 cycles.

495

496



497

498 Figure 2

499 Development of new assays for *O. volvulus. (A)* The graph represents the efficiency of

the Ov16R (red) and Ov15R (blue) in comparison with O-150 (green) across different

501 concentrations of *O. volvulus* gDNA. (B) Screening of re-designed O-150 new assays

502 (O-150 N1-N5) for limits of detection (plotted as Ct-values on the y-axis) in comparison

503 with Ov15R and current O-150 qPCR assay

504



507 Figure 3

506

Efficiency of Ov16R and O-150New (A) The VENN diagram denotes the O-150 gPCR 508 509 status of skin snips (top panel), with Ov16R detecting 17 additional samples missed by 510 O-150. (B/C) The graph represents the paired Ct values obtained by Ov16R and O150, 511 and the 17 additional samples being detected by Ov16R that were O-150 negative. (D) 512 Ov16R sensitivity is improved (Ct values) compared to O-150 but does not detect any 513 new additional samples from Loa loa co-infected area. (E) Graph depicts the correlation of the O150 assay with that of O-150New and Ov16R. (F&G) The graph shows the 514 515 paired comparison of O150New with O-150 (O-150_OLD) or Ov16R.





518 **Figure 4**

Efficacy of ccfDNA from plasma and urine. (A) the graph represents the Ov16R qPCR 519 520 status (Ct values) of ccfDNA extracted from 1000 ul, 500 ul, 250 ul and 100 ul of pooled sera (n=10) from Ov-infected individuals from Guatemala (G86), Ecuador (EC92) or 521 522 pooled plasma of healthy blood bank volunteers (n=10) with or without Ov-gDNA spiked. (B) the graph represents the Ov16R gPCR status (Ct value) with ccfDNA 523 524 extracted from 1 ml of urine from Ov-infected individuals before treatment (C&D) the 525 time course results of Ov16R qPCR with ccfDNA extracted from post-treatment samples (E) the graph represents the Ov16R status of 5 fresh urine samples from Cameroon. 526





529 **Figure 5**

528

530 Efficacy of ccfDNA from chitosan-modified filter membrane. The graph shows the

531 Ov16R qPCR (Ct values) of DNA extracted from 1 ml or 15 ml of normal urine spiked

- with varying concentrations of gDNA. The dotted lines denote the Ct values of
- 533 respective concentrations of gDNA.
- 534